A study of association of Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) and dynapenia/sarcopenia with cardio-metabolic risks

Background: The presence of sarcopenia is regarded as an important indicator of theseverity and prognosis of NAFLD, which might be extrapolated into MAFLD because ofits substantial overlap with NAFLD. The severity of NAFLD is associated with ASCVDrisk, independently of other cardiovascular risk factors. Based on these prognosticimplications of liver fibrosis and ASCVD in patients with NALFD, the severities of thesetwo factors might also differ among subgroups of patients according to MAFLD severity.• Novelty: The study will examine the association of dynapenia/sarcopenia in MAFLDwith cardio-metabolic risks which is the first study in India.• Objectives: To assess the association of Metabolic Dysfunction Associated Fatty LiverDisease (MAFLD) and dynapenia/sarcopenia with cardio-metabolic risks. Anotherobjective is to assess the prevalence of dynapenia and sarcopenia in subjects with MAFLD,to assess the association of liver fibrosis and steatosis in subjects with dynapenia andsarcopenia in MAFLD through non-invasive methods (FIB4, NFS and Fibroscan) and toassess the risk of dynapenia and sarcopenia in subjects with MAFLD and its associationwith various lifestyle, anthropometric and biochemical factors.• Methods: The study is observational with cross-sectional study design. Subjects attendingMedicine OPD will be screened for MAFLD, followed by Dynapenia/Sarcopenia.• Expected outcome: There will be significant association between MAFLD, Dynapenia orsarcopenia and ASCVD. The risk of ASCVD may be higher in subjects having bothMAFLD and dynapenia/sarcopenia.